Related Experiment Video
Updated: Apr 5, 2026
08:16
Movement Retraining using Real-time Feedback of Performance
Published on: January 17, 2013
13.9K
Advances in clinical trials for movement disorders
Karl Kieburtz1, C Warren Olanow2
1University of Rochester School of Medicine, Rochester, New York, USA.
Summary
Innovations in clinical trial design for movement disorders aid in assessing new therapies for advanced and premanifest stages. Methodological advances and regulatory changes enable more efficient, cost-effective, and timely drug development.
Area of Science:
- Neurology
- Clinical Trials
- Movement Disorders
Background:
- Clinical trials for movement disorders face challenges in advanced disease stages.
- Demonstrating disease modification and assessing premanifest interventions are key difficulties.
Purpose of the Study:
- To review recent innovations in clinical trial design for movement disorders.
- To discuss advancements in methodologies and regulatory guidelines for efficient studies.
Main Methods:
- Review of recent innovations in clinical trial design.
- Analysis of methodological advancements.
- Examination of changes in regulatory guidelines.
Main Results:
- New trial designs address challenges in advanced disease stages.
- Methods now allow for assessment of disease modification and premanifest interventions.
- Regulatory changes facilitate more efficient and cost-effective studies.
Conclusions:
- Recent innovations have significantly improved clinical trial design for movement disorders.
- Methodological and regulatory advancements streamline drug development, reducing cost and duration.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:11Clinical Trials: Overview
5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
01:16Clinical Trials
11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.2K
01:15Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K